Bank of New York Mellon Corp raised its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 161.7% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 5,304,536 shares of the medical research company’s stock after buying an additional 3,277,726 shares during the period. Bank of New York Mellon Corp’s holdings in Edwards Lifesciences Corporation were worth $627,207,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Sabal Trust CO boosted its position in shares of Edwards Lifesciences Corporation by 0.5% in the second quarter. Sabal Trust CO now owns 2,934 shares of the medical research company’s stock worth $347,000 after buying an additional 14 shares in the last quarter. Alps Advisors Inc. boosted its position in shares of Edwards Lifesciences Corporation by 0.3% in the second quarter. Alps Advisors Inc. now owns 5,102 shares of the medical research company’s stock worth $603,000 after buying an additional 14 shares in the last quarter. Alexandria Capital LLC boosted its position in shares of Edwards Lifesciences Corporation by 1.7% in the second quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock worth $136,000 after buying an additional 19 shares in the last quarter. Rehmann Capital Advisory Group boosted its position in shares of Edwards Lifesciences Corporation by 1.6% in the first quarter. Rehmann Capital Advisory Group now owns 3,393 shares of the medical research company’s stock worth $319,000 after buying an additional 55 shares in the last quarter. Finally, M Holdings Securities Inc. boosted its position in shares of Edwards Lifesciences Corporation by 1.5% in the first quarter. M Holdings Securities Inc. now owns 4,132 shares of the medical research company’s stock worth $389,000 after buying an additional 62 shares in the last quarter. Hedge funds and other institutional investors own 84.67% of the company’s stock.

Shares of Edwards Lifesciences Corporation (EW) opened at 114.83 on Wednesday. The company has a market cap of $24.25 billion, a price-to-earnings ratio of 34.83 and a beta of 0.63. The stock has a 50 day moving average of $116.72 and a 200 day moving average of $105.78. Edwards Lifesciences Corporation has a 52-week low of $81.12 and a 52-week high of $121.75.

Edwards Lifesciences Corporation (NYSE:EW) last issued its quarterly earnings data on Wednesday, July 26th. The medical research company reported $1.08 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.88 by $0.20. Edwards Lifesciences Corporation had a net margin of 22.16% and a return on equity of 27.17%. The firm had revenue of $842 million for the quarter, compared to analysts’ expectations of $839.16 million. During the same quarter in the prior year, the business earned $0.76 EPS. The business’s quarterly revenue was up 10.9% on a year-over-year basis. On average, equities research analysts expect that Edwards Lifesciences Corporation will post $3.78 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/bank-of-new-york-mellon-corp-has-627-21-million-position-in-edwards-lifesciences-corporation-ew/1495321.html.

A number of research analysts have recently issued reports on the stock. Zacks Investment Research cut shares of Edwards Lifesciences Corporation from a “buy” rating to a “hold” rating in a report on Thursday, May 18th. BidaskClub cut shares of Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 19th. Bank of America Corporation lifted their price objective on shares of Edwards Lifesciences Corporation from $140.00 to $150.00 and gave the company a “buy” rating in a report on Thursday, July 27th. SunTrust Banks, Inc. lifted their price objective on shares of Edwards Lifesciences Corporation to $14.00 and gave the company a “buy” rating in a report on Monday, July 17th. Finally, Royal Bank Of Canada lifted their price objective on shares of Edwards Lifesciences Corporation from $116.00 to $120.00 and gave the company an “outperform” rating in a report on Wednesday, April 26th. Five equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. Edwards Lifesciences Corporation presently has an average rating of “Buy” and an average target price of $121.13.

In other Edwards Lifesciences Corporation news, VP Catherine M. Szyman sold 4,681 shares of the firm’s stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $115.78, for a total transaction of $541,966.18. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Michael A. Mussallem sold 32,900 shares of the firm’s stock in a transaction that occurred on Wednesday, June 7th. The stock was sold at an average price of $118.05, for a total transaction of $3,883,845.00. The disclosure for this sale can be found here. Insiders sold a total of 171,912 shares of company stock worth $19,892,370 in the last quarter. Company insiders own 2.13% of the company’s stock.

Edwards Lifesciences Corporation Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.